The Use of Resveratrol as an Adjuvant Treatment of Pain in Endometriosis: A Randomized Clinical Trial

Daniel Mendes da Silva, Luiza Azevedo Gross, Ernesto de Paula Guedes Neto, Bruce A Lessey, Ricardo Francalacci Savaris
Journal of the Endocrine Society · 2017 · vol. 1(4) , pp. 359–369 · doi:10.1210/js.2017-00053 · PMID:29264492 · W2604333479
article OA: gold CC0 ⤵ 49 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This randomized clinical trial found that resveratrol (40 mg/d) was not superior to placebo when used as an adjuvant to oral contraceptives for reducing pain in women with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

CONTEXT: Resveratrol has been used for the treatment of endometriosis. OBJECTIVE: To compare resveratrol (40 mg/d) with monophasic contraceptive pill (COC) to COC with placebo for the reduction of pain scores. DESIGN: A randomized clinical trial. SETTING: University Hospital. PATIENTS: Women (ages 20 to 50) with laparoscopic diagnosis of endometriosis were eligible for the study. Exclusion criteria: pregnancy, allergy to resveratrol, or contraindications to COC, use of agonists of gonadotropin release hormone or danazol in the last month, or had used depot medroxyprogesterone acetate or Mirena®. INTERVENTION: Subjects were randomized using a computer-generated randomization list to receive COC for 42 days to be taken with identical capsules containing 40 mg of resveratrol or placebo in coded bottles (1:1 ratio). Allocation was concealed in coded, sequenced, opaque-sealed envelopes. MAIN OUTCOME: Median pain scores measured with a visual analog scale on day 42. RESULTS: test). Median (95% CI) difference between groups was 0.75 (-1.6 to 2.3). CONCLUSION: Resveratrol is not superior to placebo for treatment of pain in endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (54)

Cited by (49)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:20:07.505861+00:00
License: CC0 · commercial use OK